Abstract
Initial tumour burden is widely acknowledged to be a strong prognostic factor for cancer treatment, and the difference among polymetastatic and oligometastatic cancers in clinical trials is gaining the attention of oncologists. Randomised phase 3 trials represent the gold standard approach in testing new drugs against cancer. Notably, the selection of patients for inclusion in phase 3 trials relies on prespecified clinical and methodological rules (eg, clinical characteristics, randomisation procedure, and stratification factors) to keep the risk of biases affecting the strength and standardisation of results as low as possible.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
